This stock Is Quietly Engineering the Next Breakthrough in Viral Defense ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Small Caps Daily.
NanoViricides, Inc. (NYSE: NNVC) is advancing a powerful, next-generation antiviral called NV-387—and it’s showing broad-spectrum potential that could disrupt the entire antiviral landscape. - MPox, COVID-19, RSV, Influenza, H5N1 — NV-387 has shown preclinical efficacy across them all
- Oral formulation designed for frontline use in global health systems
- Described by analysts as a “paradigm shift” in antiviral therapy
Now, with traditional drugs like tecovirimat and brincidofovir falling short in MPox human trials, NNVC is moving forward with urgency. In May 2025, NNVC received regulatory ethics approval from the Democratic Republic of Congo (DRC) to begin a Phase 2 trial for MPox Clade I—the more severe strain causing endemic outbreaks across Africa. The study will be conducted in partnership with the University of Kinshasa, with manufacturing already underway and a clinical trial application expected in August. And here’s what makes this even more critical: ➡️ The U.S. Strategic National Stockpile currently holds just two approved antivirals for smallpox—and neither has proven effective for MPox in humans.
➡️ That leaves a major treatment gap—and a rare opportunity for an emerging biotech with a mutation-resistant, platform-ready antiviral. NV-387 isn’t just another one-virus drug—it’s a broad-spectrum candidate designed to stay effective even as viruses evolve. And that could be exactly what the global health system—and investors—have been waiting for. 👉Click here to see why NanoViricides (NYSE: NNVC) could be on the verge of redefining MPox treatment and unlocking a multi-billion-dollar opportunity. |
Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431 We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of NanoViricides, Inc. (NYSE American: NNVC). The compensation consists of up to $5,500 and was received/will be received from Interactive Offers. This communication should not be considered as an endorsement of the securities of adviser NanoViricides, Inc. (NYSE American: NNVC) and we are not responsible for any errors or omissions in any information provided about the securities of NanoViricides, Inc. (NYSE American: NNVC) and Interactive Offers. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 08/01/2025. Behind the Markets
Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. |
|
No comments:
Post a Comment
Keep a civil tongue.